Notice of Full Year results

RNS Number : 0268Q

Oncimmune Holdings PLC

25 October 2021

 

25 October 2021

Oncimmune Holdings plc

("Oncimmune" or the "Company")

Notice of full year results ended 31 May 2021 and investor presentations

Oncimmune Holdings plc (AIM: ONC.L), the leading global immunodiagnostics group , will be announcing its full year results for the year ended 31 May 2021 on Tuesday, 2 November 2021.

Analyst and investor presentations

Dr Adam M Hill, Chief Executive Officer, together with Matthew Hall, Chief Financial Officer, will host a virtual presentation and conference call for analysts at 10:00 GMT on the day of the results. For conference call details please contact Alex Davis of FTI Consulting at [e-mail] or 020 3727 1000.

The management team will also host on Investor Meet Company, a live presentation of the results at 15:00 GMT.

· The online presentation will be open to all existing shareholders and potential new investors

· Questions can be submitted pre-event via your Investor Meet Company dashboard up until 09:00 GMT the day before the meeting or at any time during the live presentation. Responses to the Q&A will be published at the earliest opportunity on the Investor Meet Company platform

· Investor feedback can also be submitted directly to management immediately following the event

Access to Investor Meet Company is free and interested parties can register to attend the presentation via the following link: https://www.investormeetcompany.com/oncimmune-holdings-plc/register-investor

Attendees who have already registered on the Investor Meet Company platform to meet the Company will automatically receive an invitation to the presentation.

For further information:

Oncimmune Holdings plc

Dr Adam M Hill, Chief Executive Officer

Matthew Hall, Chief Financial Officer

[e-mail]

Zeus Capital Limited (Nominated Adviser and Joint Broker)

Andrew Jones, Daniel Harris, James Hornigold

[phone]

Singer Capital Markets (Joint Broker)

Aubrey Powell, Harry Gooden, George Tzimas, James Fischer

[phone]

WG Partners (Joint Broker)

David Wilson, Nigel Barnes, Nigel Birks

[phone]

Media enquiries:

FTI Consulting

Ben Atwell, Michael Trace, Alex Davis

[e-mail]

[phone]

About Oncimmune

Oncimmune is a leading immunodiagnostics developer, primarily focused on the growing fields of immuno-oncology, autoimmune disease and infectious diseases. Oncimmune has a diversified and growing revenue both from its portfolio of diagnostic products to detect early-stage cancer and its contract discovery and development service business whose platform delivers actionable insights into therapies to the Company's pharmaceutical and biotech partners .

Our understanding of the immune system enables us to harness its sophisticated response to disease to detect cancer earlier and to support the development of better therapies. The key to improving cancer survival is early detection and better selection for therapy. As a company, we are driven by our passion to improve cancer survival and to give people extra time.

Oncimmune's ImmunoINSIGHTS platform enables life science organisations to optimise drug development and delivery, leading to more effectively targeted and safer treatments for patients. Oncimmune's immunodiagnostic technology, EarlyCDT, can detect and help identify cancer on average four years earlier than standard clinical diagnosis. Our lead diagnostic test, EarlyCDT Lung, targets a vast market estimated to grow to £3.8bn by 2024. With over 200,000 tests already performed for patients worldwide and its use being supported by peer reviewed data in over 12,000 patients, we are poised to become an integral component of future lung cancer detection programmes, globally.

Oncimmune's diagnostic products business is located at its laboratory facility in Nottingham, UK and its ImmunoINSIGHTS service business at its discovery research centre in Dortmund, Germany. The ImmunoINSIGHTS business development team are based in the US and Oncimmune is seeking to replicate the Dortmund facility in the US in the medium term.

For more information, visit  www.oncimmune.com

 

END

 

 

NORGZMZGGDFGMZZ